Yuanhong Xu

Yuanhong Xu

Auto-generated profile, based on publicly available information

Yuanhong Xu

The First Hospital of China Medical University, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in CCS Chemistry
Verified
Journal Article
Open access
KZKaixiang Zhang
Kaixiang Zhang
YLYanan Li
Yanan Li
JLJunjie Liu
Junjie Liu
XYXue Yang
Xue Yang
YXYuanhong Xu
Yuanhong Xu
Jinghong LiJinghong Li
Jinghong Li
Oligonucleotide drugs have been used widely as therapeutic agents for gene therapy, while their instability in biological media and inefficiency for intracellular delivery remain major hurdles for ... Description

1 January 2022 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
TDTiancong Du
Tiancong Du
KZKe Zhang
Ke Zhang
ZZZhongbo Zhang
Zhongbo Zhang
AGAijia Guo
Aijia Guo
GYGuilin Yu
Guilin Yu
YXYuanhong Xu
Yuanhong Xu
Pancreatic cancer (PC) is one of the malignant tumors with the worst prognosis worldwide because of a lack of early diagnostic markers and efficient therapies. Integrin, beta-like 1 (ITGBL1) is a β-integrin-related extracellular matrix protein and is reported to promote progression of some types of cancer. Nevertheless, the function of ITGBL1 in PC is still not clear. Herein, we found that ITGBL1 was highly expressed in PC tissues compared to normal tissues (P<0.05) and PC patients with higher TGBL1 expression showed worse prognosis. PANC-1 and AsPC-1 cells were used for gain/loss-of-function experiments. We found that ITGBL1-silenced cells exhibited decreased proliferation, migration, and invasion abilities and delayed cell cycle, whereas ITGBL1 overexpression reversed these malignant behaviors. ITGBL1 was also demonstrated to activate the TGF-β/Smad pathway, a key signaling pathway in PC progression. Additionally, ITGBL1 expression was found to be suppressed by a suppressor of PC progression, c-Jun dimerization protein 2 (JDP2). Results of dual-luciferase assay indicated that transcription factor JDP2 could inhibit TGBL1 promoter activity. ITGBL1 overexpression inversed the effects of JDP2 up-regulation on cell function. Collectively, we concluded that ITGBL1 may be transcriptionally suppressed by JDP2 and promote PC progression through the TGF-β/Smad pathway, indicating that ITGBL1 may have therapeutic potential for the treatment of PC.

1 May 2021 in Gland Surgery
Verified
Journal Article
Open access
PDF file
ZLZhe Liu
Zhe Liu
GLGuichen Li
Guichen Li
AGAnjiang Gou
Anjiang Gou
ZXZhihuan Xiao
Zhihuan Xiao
YXYuanhong Xu
Yuanhong Xu
GMGang Ma
Gang Ma
Inflammatory myofibroblastic tumor (IMT) is a rare disease of unknown etiology. It usually occurs in abdominal soft tissues and lung, and is extremely rare in the pancreas. IMT can occur in any part of a person at any age, however, it mostly affects children and young people. Its clinical manifestations are atypical, imaging examinations are not specific, and the differential diagnosis of pancreatic malignancies is difficult, making it easily misdiagnosed. Surgical resection is the preferred method of treatment for IMT. In this case report, we report a rare case of IMT in the neck of the pancreas and reviewed the relevant literature. In our case, the patient was a 57-year-old woman with an IMT in the neck of the pancreas. Abdominal pain was the only clinical symptom, and imaging features were not specific. She underwent surgery to remove the pancreatic mass, and the final diagnosis of IMT was based on histopathology and immunohistochemistry. After 6 months of regular follow-up, the patient had no complications or further incidents. The purpose is to emphasize the difficulty of the preoperative diagnosis of pancreatic IMT and the difficulty of distinguishing it from pancreatic malignancies. It is hoped that clinicians can gain a deeper understanding of pancreatic IMT through this case report.